Advertisement |
 |
Discover Research Partnerships with Boehringer Ingelheim Our research teams know that they can only tackle some of the most important challenges in medicine today if we work together with colleagues outside our organisation. We invite academic institutions, non-profit research centres and external industry partners to help us deliver a better future for patients.
Visit http://discoveringtogether.boehringer-ingelheim.com |  |
|
|
 |
 |
TABLE OF CONTENTS
|
25 October 2013 |
 |  |  |
 | News
Analysis
Research Highlights
Research & Reviews
Careers
| |
Nature Reviews Drug Discovery is on Twitter |  |
 |
 |
Advertisement |
 |
Special section on epigenomics The special section on epigenomics in the July 2013 issue of Journal of Human Genetics features review and original articles by top-level epigenetic researchers, and covers various topics of epigenetic research, both basic and clinical. Take advantage of FREE access to select articles today! | |
|
|
 |
|
News | Top |
 |
 |
 |
Neurodevice startups target peripheral nervous system doi:10.1038/nbt1013-865 GlaxoSmithKline recently announced their US$50-million Action Potential Venture Capital funding program to support the nascent neuroengineering industry. Full Text
|
 |
 |
 |
Polypill improves adherence but fails to win all scientists' hearts doi:10.1038/nm1013-1192 Rolling a statin, an aspirin, a B vitamin and three blood pressure-lowering drugs into a single so-called polypill could help patients stay on their medication, but more research is needed to see whether this increased adherence leads to fewer cardiovascular events in the long run. Full Text
|
 |
 |
 |
China clampdown on GSK linked to drug costs doi:10.1038/nbt1013-861 China unleashed a crackdown on the pharma industry over accusations of bribery and misconduct, which analysts suggest is intended to ultimately push down drug prices in the Chinese pharma market. Full Text
|
 |
 |
 |
Scripps boosts research coffers by selling reagents to Sigma-Aldrich doi:10.1038/nbt1013-862b Six high-profile laboratories at The Scripps Research Institute have entered an alliance with Sigma-Aldrich with the aim of improving the coordination between reagent discovery and commercialization. Full Text
|
 |
Analysis | Top |
 |
 |
 |
Revving up cGAS doi:10.1038/scibx.2013.1117 Researchers have confirmed the role of cyclic GMP-AMP signaling in the innate immune system, making a case for developing adjuvants that agonize the pathway or antagonists of the pathway to treat autoimmune conditions. Full Text
|
 |
 |
 |
Pharmaceutical forecasting: throwing darts? doi:10.1038/nrd4127 Forecasting of the future commercial value of drugs is a crucial activity that affects many decisions by pharmaceutical companies. However, this analysis indicates that many forecasts are wrong, often substantially. Full Text
|
 |
Research Highlights | Top |
 |
 |
 |
Anticancer drugs: Stapled peptide reactivates p53 doi:10.1038/nrd4133 The stapled α-helical peptide ATSP-7041 - which is a specific dual inhibitor of MDM2 and MDMX - effectively induces p53-dependent apoptosis and inhibits cell proliferation in mouse models of human tumours. Full Text
|
 |
 |
 |
Biotechnology: Rice-derived rotavirus antibody shows promise doi:10.1038/nrd4131 Researchers have genetically engineered rice to produce high yields of a rotavirus-specific antibody fragment in the seeds. This antibody was effective in treating and preventing rotavirus-induced gastrointestinal symptoms in mice. Full Text
|
 |
 |
 |
Neurodegenerative diseases: New kinase targets for Alzheimer's disease doi:10.1038/nrd4132 Two recent studies show that inhibiting kinases involved in the regulation of amyloid precursor protein processing or protein synthesis by eukaryotic translation initiation factor 2α attenuates disease progression in mice. Full Text
|
 |
Research & Reviews | Top |
 |
 |
 |
|
 |
No comments:
Post a Comment